Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Open access
Karn, T., Denkert, C., Weber, K.E., Holtrich, U., Hanusch, C., Sinn, B.V., Higgs, B.W., Jank, P., Sinn, H.P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W.D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P.A., Jackisch, C., Untch, M., Schneeweiss, A., Loibl, S. · 2020 · Annals of Oncology

Abstract

BACKGROUND The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast cancer (TNBC) is currently not known, neither for immune checkpoint blockade (ICB) nor conventional chemotherapy. PATIENTS AND METHODS We obtained both whole exome sequencing and RNA-Seq data from pre-treatment samples of 149 TNBC of the recent neoadjuvant ICB trial GeparNuevo. In a predefined analysis, we assessed the predictive value of TMB and a previously developed immune GEP for pathological complete remission (pCR). RESULTS Median TMB was 1.52 mut/Mb (range 0.02-7.65) and was significantly higher in patients with pCR (median 1.87 vs. 1.39; P=0.005). In multivariate analysis, odds ratios for pCR per mut/Mb were 2.06 (95% CI 1.33-3.20, P=0.001) among all patients, 1.77 (95% CI 1.00-3.13, P=0.049) in the durvalumab treatment arm, and 2.82 (95% CI 1.21-6.54, P=0.016) in the placebo treatment arm, respectively. We also found that both continuous TMB and immune GEP (or tumor infiltrating lymphocytes) independently predicted pCR. When we stratified patients in groups based on the upper tertile of TMB and median GEP, we observed a pCR rate of 82% (95% CI 60%-95%) in the group with both high TMB and GEP, in contrast to only 28% (95% CI 16%-43%) in the group with both low TMB and GEP. CONCLUSIONS TMB and immune gene expression profile add independent value for pCR prediction. Our results recommend further analysis of TMB in combination with immune parameters to individually tailor therapies in breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.05.015

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 224

Metadata

Authors
Karn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H. P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W. D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P. A., Jackisch, C., Untch, M., Schneeweiss, A., & Loibl, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-09
Volume
31
Issue
9
Pages
1216-1222
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3027534983
Cited by
224
References
11
FWCI
11.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.